The antiviral activity of rodent and lagomorph SERINC3 and SERINC5 is counteracted by known viral antagonists

• Type: Article in International Scientific Journal
• Date: 2019

Authors

de Sousa Pereira, P (Author) Other; Abrantes, J (Author) FCUP; Bauernfried, S (Author) Other; Pierini, V (Author) Other; Esteves, PJ (Author) FCUP; Keppler, OT (Author) Other; Pizzato, M (Author) Other; Hornung, V (Author) Other; Fackler, OT (Author) Other; Baldauf, HM (Author) Other

Journal

Title: Journal of General Virology

Vol. 100

Pages: 278-288

ISSN: 0022-1317

Publisher: Microbiology Society

Indexing

ISI Web of Knowledge - 13 Citations

Scopus - 13 Citations

Other information

Authenticus ID: P-00Q-6FM

DOI: 10.1099/jgv.0.001201

Abstract (EN): A first step towards the development of a human immunodeficiency virus (HIV) animal model has been the identification and surmounting of species-specific barriers encountered by HIV along its replication cycle in cells from small animals. Serine incorporator proteins 3 (SERINC3) and 5 (SERINC5) were recently identified as restriction factors that reduce HIV-1 infectivity. Here, we compared the antiviral activity of SERINC3 and SERINC5 among mice, rats and rabbits, and their susceptibility to viral counteraction to their human counterparts. In the absence of viral antagonists, rodent and lagomorph SERINC3 and SERINC5 displayed anti-HIV activity in a similar range to human controls. Vesicular stomatitis virus G protein (VSV-G) pseudotyped virions were considerably less sensitive to restriction by all SERINC3/5 orthologs. Interestingly, HIV-1 Nef, murine leukemia virus (MLV) GlycoGag and equine infectious anemia virus (EIAV) S2 counteracted the antiviral activity of all SERINC3/5 orthologs with similar efficiency. Our results demonstrate that the antiviral activity of SERINC3/5 proteins is conserved in rodents and rabbits, and can be overcome by all three previously reported viral antagonists.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 11